TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02600520

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRP with RSV gel LDD
Description: After SRP, 1.2% Rosuvastatin (RSV) gel was delivered subgingivally into the pocket

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRP with ATV gel LDD
Description: After SRP, 1.2% Atorvastatin (ATV) gel was delivered subgingivally into the pocket

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SRP with placebo gel LDD
Description: After SRP, placebo gel was delivered subgingivally into the pocket
Study: NCT01068743

Intervention type: DRUG
Group type: OTHER
Intervention: saxagliptin
Description: Tablets, Oral, 2.5 mg, once daily, single dose
Study: NCT02806414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Study: NCT04256447

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary sodium concentrations
Description: The urinary sodium excretion was measured using an immunochemical methodology
Study: NCT01068743

Intervention type: DRUG
Group type: OTHER
Intervention: saxagliptin
Description: Tablets, Oral, 2.5 mg, once daily, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: metformin
Description: Tablets, Oral, 850 mg, once daily, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: metformin
Description: Tablets, Oral, 850 mg, once daily, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: saxagliptin + metformin (FDC tablet)
Description: Tablet, oral, (saxagliptin 2.5 mg) (metformin 850 mg), once daily, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: saxagliptin + metformin (FDC tablet)
Description: Tablet, oral, (saxagliptin 2.5 mg) (metformin 850 mg), once daily, single dose
Study: NCT00293293

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: healing touch
Description: The practitioner performed a structured interview with the patient both a verbal assessment and an energy/physical assessment using pendulum and hand scan techniques. The practitioner will then provide the intervention which will consist of: chakra connection, magnetic passes (hands still and in motion), magnetic clearing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage therapy
Description: Standard massage techniques will be employed over the head, neck, shoulders, back, hands, and/or feet areas. The intensity and rapidity of massage movements will be individualized to the patient's comfort level.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypnosis
Description: Steps: 1) begins with a progressive relaxation induction; 2) suggestions for deepening are then provided; 3) offered suggestions to increase comfort with medical procedures; 4) suggestion for enhanced capacity for coping will be given as an ego strengthening suggestion, with a post-hypnotic suggestion for increasing comfort/success in coping each time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard chemotherapy
Description: Patients will receive 6 cycles of taxane and platinum therapy as prescribed by their treating physician. Chemotherapy treatment is not part of this study.
Study: NCT01472003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-806
Description: ABT-806 will be administered by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-806i
Description: ABT-806i will be administered by intravenous infusion.
Study: NCT03488251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3724
Description: MT-3724 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3724
Description: MT-3724 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3724
Description: MT-3724 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3724
Description: MT-3724 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered.
Study: NCT00011531

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Prevention of Pressure Ulcers
Study: NCT02038868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP4901
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT01778283

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Acetate-free dialysis solution
Description: the hemodialysis solution that does not contain acetate as buffer

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acetate-free dialysis solution
Description: the hemodialysis solution that does not contain acetate as buffer
Study: NCT04107402

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of coagulopathy, Platelets activation and Platelets-Neutrophils interplay
Description: Blood sample Urine Sample Pulmonary, hepatic and cardiac tissue from biopsy and autopsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of coagulopathy, Platelets activation and Platelets-Neutrophils interplay
Description: Blood sample Urine Sample Pulmonary, hepatic and cardiac tissue from biopsy and autopsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of coagulopathy, Platelets activation and Platelets-Neutrophils interplay
Description: Blood sample Urine Sample Pulmonary, hepatic and cardiac tissue from biopsy and autopsy
Study: NCT03488251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered.
Study: NCT00353496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lanreotide (Autogel formulation)
Description: 120mg administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.
Study: NCT01150357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren (6.25/12.5/25 mg)
Description: Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the low dose arm, participants used one or more of the 6.25 mg capsule (containing 2 minitablets) once daily to reach the body-weight stratified dose of aliskiren.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren (37.5/75/150 mg)
Description: Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the medium dose arm, participants used one or more of the 37.5 mg capsule (containing 12 minitablets) once daily to reach the body- weight stratified dose of aliskiren.
Study: NCT00353496

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution 0.9% administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.
Study: NCT01842607

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab (a fully humanised IgG antibody) 100 mg injected SC once every 4 weeks for 12 months. Mepolizumab will be provided as a lyophilised cake in sterile vials
Study: NCT00745186

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagen
Description: 0.2 mg or 1 mg Glucagen single injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mayne Glucagon
Description: 0.2 mg or 1 mg Mayne Glucagon
Study: NCT01150357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren (150/300/600 mg)
Description: Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the high dose arm, participants used one or more of the 150 mg capsule (containing 48 minitablets) once daily to reach the body- weight stratified dose of aliskiren.
Study: NCT00971789

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Fludeoxyglucose is the radioactive material/compound used as an injection to have a PET scan performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: sirolimus 6 mg by mouth loading dose and 2 mg by mouth daily in a 28 day treatment cycle. Patients who do not have cancer take the drug for a total of two cycles (56 days) unless they develop unacceptable side effects. Those who have cancer may continue sirolimus beyond cycle 2 until their disease worsens or they develop unacceptable side effects

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Videography
Description: This examination involves testing of cerebellar function that controls movement, balance, and coordination.
Study: NCT01261910

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive initial education
Description: Participants will (1) view a video, brochure, and fact sheet regarding living kidney donation, and (2) discuss the videos and materials with a transplant educator, in-person.
Study: NCT03224715

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DNA Repair Enzyme Cream
Description: ver-the-counter cosmeceutical. We were going to be using it adjunctively before standard treatment of the actinic cheilitis was done
Study: NCT01029834

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: family based lifestyle and behavioral counseling
Description: 16 group meetings

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: counseling focused on the child
Description: 16 meetings
Study: NCT03243071

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Website
Description: Participants randomized to the intervention arm will have free access to a password protected interactive culturally and linguistically tailored website via a tablet device. No private identifiable data about you will be collected. Participants will receive a brief 10-minute tutorial by a trained research assistant on login procedures and use of the website.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Website
Description: Participants randomized to the control condition will have free access to the NYU standard clinical trials website. Participants in the control condition will have access to the tailored website at the date of study completion (no later than 6 months' post-date of enrollment).
Study: NCT02761252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine 20mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bilastine 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast 10mg
Study: NCT03460067

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Omission of Radiation
Description: No Radiation will be given. 1 year of trastuzumab +/- pertuzumab treatment will be given with 5 years of follow up occurring every 3 months to check for recurrence
Study: NCT05248971

Intervention type: OTHER
Intervention: Trauma-focused cognitive behavioral therapy (TF-CBT)
Description: TF-CBT is an evidence-based treatment method for children and adolescents who have been exposed to trauma and experience posttraumatic stress symptoms. The treatment model has a family and caregiver focus, and non-offending caregivers are included in the treatment. TF-CBT is normally provided through 8-12 treatment sessions.
Study: NCT00808730

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fiberoptic fibroscopy
Description: Bronchial specimens will be obtained by fiberoptic bronchoscopy within 15 days after the enrolment
Study: NCT02500264

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Study: NCT02761252

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Bilastine 20mg
Study: NCT00952263

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MBL-HCV1
Description: Single infusion of MBL-HCV1 at escalating doses as determined by cohort assignment: Cohort 1 @ 1 mg/kg, Cohort 2 @ 3 mg/kg, Cohort 3 @ 10 mg/kg, Cohort 4 @ 30 mg/kg, Cohort 5 @ 50 mg/kg.
Study: NCT02752568

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endometrial scratch
Description: midluteal endometrial scratch using Novak curette under general anesthesia in the cycle preceding stimulation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: assisted hatching
Description: using Octax laser 20120644-laser 5452

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: controlled ovarian hyperstimulation
Description: using merional\&/ or fostimon doses individualized as judged by patient age \& ovarian reserve \& monitored by follicular size \& serum estradiol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: controlled ovarian hyperstimulation
Description: using merional\&/ or fostimon doses individualized as judged by patient age \& ovarian reserve \& monitored by follicular size \& serum estradiol

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: controlled ovarian hyperstimulation
Description: using merional\&/ or fostimon doses individualized as judged by patient age \& ovarian reserve \& monitored by follicular size \& serum estradiol
Study: NCT02431468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bryostatin 1
Description: The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution. Placebo is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution.
Study: NCT03385824

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Advocacy for Independent Life (SAIL)
Description: SAIL program is based on an interactive workshop model. In -person sessions will focus on: enhancement of self-efficacy beliefs; enhancement of knowledge of TBI self-advocacy information; group process to instill hope and universality; and practice of self-advocacy behaviors in a supportive neuro-rehabilitation structured group environment.
Study: NCT04010006

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4K Laparoscopic Surgery
Description: 4K Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HD Laparoscopic Surgery
Description: HD Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
Study: NCT06554158

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: De-escalation of Adjuvant Radiotherapy
Study: NCT02431468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bryostatin 1
Description: The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution. Placebo is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the active drug, intended for IV infusion upon reconstitution and dilution.
Study: NCT03583125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EOC317
Description: tablet(s) PO
Study: NCT03180489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin Tablet
Description: Daily oral administration of dapagliflozin with dietary counseling to promote weight loss. Dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: Daily administration of placebo tablet with dietary counseling to promote weight loss. Matching placebo for dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
Study: NCT01858610

Intervention type: DRUG
Group type: OTHER
Intervention: Irbeasartan/hydrochlorothiazide

Intervention type: DRUG
Group type: OTHER
Intervention: Irbesartan

Intervention type: DRUG
Group type: OTHER
Intervention: Hydrochlorothiazide
Study: NCT04062994

Intervention type: BEHAVIORAL
Intervention: Nudge to reduce intraoperative hypotension
Description: Providers will be alerted if their patients are at high risk of hypotension or at increased risk of sequelae from hypotension. Intraoperatively, if patients have more than 10 minutes of hypotension an alert will be displayed on the screen.
Study: NCT03676751

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Zithromax® for oral suspension is supplied in bottles containing azithromycin dehydrate powder equivalent to 1200mg per bottle and the following inactive ingredients: sucrose; tribasic anhydrous sodium phosphate; hydroxypropyl cellulose; xanthan gum; FD\&C Red #40; and flavoring including spray dried artificial cherry, crème de vanilla, and banana. After constitution, a 5mL suspension contains 200mg of azithromycin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral suspension of placebo for azithromycin
Study: NCT04445220

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SBI-101
Description: SBI-101 is a biologic/device combination product that combines two components: allogeneic human mesenchymal stromal cells (MSCs) and an FDA-approved plasmapheresis device. SBI-101 is administered via integration into a Continuous Renal Replacement Therapy circuit and is designed to regulate inflammation and promote repair of injured tissue.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SBI-101
Description: SBI-101 is a biologic/device combination product that combines two components: allogeneic human mesenchymal stromal cells (MSCs) and an FDA-approved plasmapheresis device. SBI-101 is administered via integration into a Continuous Renal Replacement Therapy circuit and is designed to regulate inflammation and promote repair of injured tissue.
Study: NCT01014416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan 15mg or 30mg or 60mg or Placebo
Description: Single dose of Tolvaptan 15mg or 30mg or 60mg or Placebo per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan 15mg or 30mg or 60mg or Placebo
Description: Single dose of Tolvaptan 15mg or 30mg or 60mg or Placebo per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan 15mg or 30mg or 60mg or Placebo
Description: Single dose of Tolvaptan 15mg or 30mg or 60mg or Placebo per day
Study: NCT02994355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systems Analysis and Improvement Approach
Description: 1. Understanding the cascade from FP clinic enrollment to HIV testing~2. Use process mapping to identify modifiable bottlenecks~3. Define and implement workflow adaptations to eliminate modifiable bottlenecks~4. Monitor change in performance~5. Repeat the analysis and improvement cycle (steps 1-4)
Study: NCT03399318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 30 mg/kg load then 15mg/kg Q6 hours for the Aggressive Antipyretic Arm~Acetaminophen is also given to children in the placebo arm when they have a fever over 38.5 degrees Celsius during scheduled clinical assessments

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 10 mg/kg Q6 hours for the Aggressive Antipyretic Arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for acetaminophen
Description: placebo for acetaminophen for children in the Usual Care arm~For children in the Aggressive Antipyretic Arm, when they have a temperature over 38.5 degrees Celsius they are treated with a placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for ibuprofen
Description: placebo for ibuprofen
Study: NCT02918747

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegaspargase
Description: P-Gemoxd Arm: 2000U/m2 im on day 1 of each 21 day cycle. Number of Cycles: four.~P-CHOP Arm: 2000U/m2 im on day 2 of each 21 day cycle. Number of Cycles: four.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: P-Gemoxd Arm: 2000U/m2 im on day 1 of each 21 day cycle. Number of Cycles: four.~P-CHOP Arm: 2000U/m2 im on day 2 of each 21 day cycle. Number of Cycles: four.
Study: NCT02872038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefepime
Description: Cefepime intraperitoneal continuous dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin plus Ceftazidime
Study: NCT00725088

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Exercise training
Study: NCT03571490

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Single shot of ropivacaine 0.325%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Single shot of saline 0.9%
Study: NCT01143220

Intervention type: OTHER
Intervention: No specific interventions
Description: Observational investigation, only procedures according to local hospital standard.
Study: NCT04077177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Male Athlete Body Project
Description: Participants who meet eligibility criteria and consent to the study will be randomized to one of two conditions: intervention condition (i.e., Male Athlete Body Project) or an assessment only control condition. The intervention groups will take place at IIT. Participants who accept randomization to condition will complete baseline questionnaires after randomization (immediately prior to Session 1 in the intervention condition and after being randomized to the assessment only control condition). Questionnaires will be repeated immediately post-intervention (intervention condition)/after a 3-week interval (control). All participants will be asked to complete the questionnaires again, 4 weeks after the previous round of questionnaires. The 3, 80-minute group sessions will be separated by 1 week.
Study: NCT01352429

Intervention type: RADIATION
Intervention: Proton Therapy

Intervention type: RADIATION
Intervention: Proton Therapy

Intervention type: RADIATION
Intervention: IMRT

Intervention type: RADIATION
Intervention: IMRT
Study: NCT00619996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar)
Description: Sorafenib 400 mg bid orally continuously~Sorafenib will be administered from the start of treatment in combination with Docetaxel until progression of disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/mq ev g1 every 21 days. Docetaxel will be administered for a maximum of 9 cycles.